{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T02:18:52Z","timestamp":1789611532242,"version":"build-2803163510"},"reference-count":38,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jiac.2025.102704","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T11:39:29Z","timestamp":1744285169000},"page":"102704","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Isavuconazole in chronic pulmonary aspergillosis: What is the evidence?"],"prefix":"10.1016","volume":"31","author":[{"given":"Vitor Falc\u00e3o","family":"de Oliveira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariane","family":"Taborda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9ssica Toshie","family":"Katayose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno Victor","family":"dos Santos Prates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isadora Cristina","family":"de Souza Ritter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana Satie","family":"Gon\u00e7alves Kono Magri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0765-6654","authenticated-orcid":false,"given":"Edson","family":"Abdala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7996-8265","authenticated-orcid":false,"given":"Marcello Mihailenko Chaves","family":"Magri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"165","key":"10.1016\/j.jiac.2025.102704_bib1","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3004404","article-title":"Hidden killers: human fungal infections","volume":"4","author":"Brown","year":"2012","journal-title":"Sci Transl Med"},{"issue":"7","key":"10.1016\/j.jiac.2025.102704_bib2","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/S1473-3099(22)00057-3","article-title":"Efficacy of 12-months oral itraconazole versus 6-months oral itraconazole to prevent relapses of chronic pulmonary aspergillosis: an open-label, randomised controlled trial in India","volume":"22","author":"Sehgal","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"10.1016\/j.jiac.2025.102704_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0240374","article-title":"Tolerability of oral itraconazole and voriconazole for the treatment of chronic pulmonary aspergillosis: a systematic review and meta-analysis","volume":"15","author":"Olum","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.jiac.2025.102704_bib4","article-title":"Chronic pulmonary aspergillosis: comprehensive insights into epidemiology, treatment, and unresolved challenges","volume":"11","author":"Tashiro","year":"2024","journal-title":"Ther Adv Infect Dis"},{"issue":"1","key":"10.1016\/j.jiac.2025.102704_bib5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1183\/13993003.00583-2015","article-title":"Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management","volume":"47","author":"Denning","year":"2016","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.jiac.2025.102704_bib6","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000489474","article-title":"Treatment of chronic pulmonary aspergillosis: current standards and future perspectives","volume":"96","author":"Alastruey-Izquierdo","year":"2018","journal-title":"Respiration"},{"issue":"6","key":"10.1016\/j.jiac.2025.102704_bib7","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02950-2021","article-title":"Treatment outcome definitions in chronic pulmonary aspergillosis: a CPAnet consensus statement","volume":"59","author":"Van Braeckel","year":"2022","journal-title":"Eur Respir J"},{"issue":"10020","key":"10.1016\/j.jiac.2025.102704_bib8","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jiac.2025.102704_bib9","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3324\/haematol.2016.152900","article-title":"ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients","volume":"102","author":"Tissot","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.jiac.2025.102704_bib10","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jiac.2025.102704_bib11","series-title":"A65. Fungi chronicles","article-title":"Unique case of chronic pulmonary aspergillosis: unraveling potential risk factors in an immunocompetent patient with marijuana use and malnutrition","author":"Anbar","year":"2024"},{"key":"10.1016\/j.jiac.2025.102704_bib12","series-title":"A65. Fungi chronicles","article-title":"An indolent case of chronic cavitary pulmonary aspergillosis","author":"Friedman","year":"2024"},{"key":"10.1016\/j.jiac.2025.102704_bib13","first-page":"A1899","article-title":"Bronchoscopic removal of recurrent, bilateral aspergillomas in a person with cystic fibrosis (pwcf) who underwent double lung transplant with polymicrobial pulmonary colonization and a trial of preprocedural antibiotics","author":"Lalonde","year":"2024","journal-title":"A49. Research studies and case reports in interventional pulmonary and pleural disease. American Thoracic Society"},{"issue":"2","key":"10.1016\/j.jiac.2025.102704_bib14","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jiac.2022.10.010","article-title":"Efficacy and safety of isavuconazole against deep-seated mycoses: a phase 3, randomized, open-label study in Japan","volume":"29","author":"Kohno","year":"2023","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2025.102704_bib15","article-title":"CT-guided microwave ablation of the nonsurgical aspergilloma","volume":"44","author":"Devine","year":"2023","journal-title":"Respir Med Case Rep"},{"key":"10.1016\/j.jiac.2025.102704_bib16","article-title":"A case of massive hemoptysis due to pulmonary aspergilloma","author":"Bishnoi","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.jiac.2025.102704_bib17","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/myc.12885","article-title":"Isavuconazole and voriconazole for the treatment of chronic pulmonary aspergillosis: a retrospective comparison of rates of adverse events","volume":"62","author":"Bongomin","year":"2019","journal-title":"Mycoses"},{"issue":"6","key":"10.1016\/j.jiac.2025.102704_bib18","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1007\/s11096-022-01521-5","article-title":"Isavuconazole: does the unique in label regimen fit for a cachectic elderly? - 50th ESCP Symposium on Clinical Pharmacy, Polypharmacy and ageing - highly individualized, interprofessional, person-centered care : 19-21 October 2022, Prague, Czech Republic","volume":"44","author":"Sophia","year":"2022","journal-title":"Int J Clin Pharm"},{"issue":"1","key":"10.1016\/j.jiac.2025.102704_bib19","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01511-20","article-title":"Isavuconazole therapeutic drug monitoring during long-term treatment for chronic pulmonary aspergillosis","volume":"65","author":"Kosmidis","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2025.102704_bib20","first-page":"A6856","article-title":"Aspergilloma in lung transplant recipient 8 Years post-transplant: should prolonged anti-fungal prophylaxis Be Re-visited? D59. Fungal infection case reports","author":"Pennington","year":"2019","journal-title":"American Thoracic Society"},{"issue":"6","key":"10.1016\/j.jiac.2025.102704_bib21","doi-asserted-by":"crossref","first-page":"459","DOI":"10.18176\/jiaci.0424","article-title":"Successful treatment of chronic pulmonary aspergillosis with isavuconazole","volume":"29","author":"Guillen Vera","year":"2019","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jiac.2025.102704_bib22","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.mmcr.2018.07.006","article-title":"Late-onset isavuconazole-induced liver injury","volume":"22","author":"Bongomin","year":"2018","journal-title":"Med Mycol Case Rep"},{"key":"10.1016\/j.jiac.2025.102704_bib23","first-page":"53","article-title":"Isavuconazole levels in patients on long-term therapy for chronic pulmonary aspergillosis - poster Presentations","volume":"60","author":"Richardson","year":"2017","journal-title":"Mycoses"},{"key":"10.1016\/j.jiac.2025.102704_bib24","first-page":"53","article-title":"Tolerability of isavuconazole by patients previously intolerant to other azoles treated for chronic pulmonary aspergillosis - poster Presentations","volume":"60","author":"Bongomin","year":"2017","journal-title":"Mycoses"},{"key":"10.1016\/j.jiac.2025.102704_bib25","article-title":"Endobronchial aspergilloma: a rare presentation of pulmonary aspergillosis","author":"Sutherland","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.jiac.2025.102704_bib26","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s11046-022-00676-z","article-title":"Challenges, characteristics, and outcomes of chronic pulmonary aspergillosis: a 11-year experience in A middle-income country","volume":"188","author":"de Oliveira","year":"2023","journal-title":"Mycopathologia"},{"issue":"7","key":"10.1016\/j.jiac.2025.102704_bib27","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1080\/17476348.2020.1750956","article-title":"An overview of the available treatments for chronic cavitary pulmonary aspergillosis","volume":"14","author":"Sehgal","year":"2020","journal-title":"Expet Rev Respir Med"},{"issue":"5","key":"10.1016\/j.jiac.2025.102704_bib28","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/myc.12075","article-title":"Itraconazole in chronic cavitary pulmonary aspergillosis: a randomised controlled trial and systematic review of literature","volume":"56","author":"Agarwal","year":"2013","journal-title":"Mycoses"},{"issue":"9","key":"10.1016\/j.jiac.2025.102704_bib29","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/myc.13324","article-title":"Anti-fungal agents in the treatment of chronic pulmonary aspergillosis: systematic review and a network meta-analysis","volume":"64","author":"Sehgal","year":"2021","journal-title":"Mycoses"},{"key":"10.1016\/j.jiac.2025.102704_bib30","article-title":"Mortality in chronic pulmonary aspergillosis: a systematic review and individual patient data meta-analysis","volume":"28","author":"Sengupta","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.jiac.2025.102704_bib31","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/s12281-017-0304-7","article-title":"The management of chronic pulmonary aspergillosis: the UK national aspergillosis centre approach","volume":"11","author":"Maghrabi","year":"2017","journal-title":"Curr Fungal Infect Rep"},{"issue":"12","key":"10.1016\/j.jiac.2025.102704_bib32","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1016\/j.clinthera.2022.10.005","article-title":"Clinical practice guideline for the therapeutic drug monitoring of voriconazole in non-Asian and Asian adult patients: consensus review by the Japanese society of chemotherapy and the Japanese society of therapeutic drug monitoring","volume":"44","author":"Takesue","year":"2022","journal-title":"Clin Ther"},{"issue":"5","key":"10.1016\/j.jiac.2025.102704_bib33","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s11046-023-00781-7","article-title":"Itraconazole serum trough concentrations using oral capsules for the treatment of chronic pulmonary aspergillosis: what is the target?","volume":"188","author":"de Oliveira","year":"2023","journal-title":"Mycopathologia"},{"issue":"4","key":"10.1016\/j.jiac.2025.102704_bib34","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/FTD.0000000000000524","article-title":"Validation of an isavuconazole high-performance liquid chromatography assay in plasma for routine therapeutic drug monitoring applications","volume":"40","author":"Mueller","year":"2018","journal-title":"Ther Drug Monit"},{"issue":"8","key":"10.1016\/j.jiac.2025.102704_bib35","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1093\/jac\/dkz188","article-title":"Serial monitoring of isavuconazole blood levels during prolonged antifungal therapy","volume":"74","author":"Furfaro","year":"2019","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"10.1016\/j.jiac.2025.102704_bib36","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01034-17","article-title":"Exposure-response relationships for isavuconazole in patients with invasive aspergillosis and other filamentous fungi","volume":"61","author":"Desai","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.jiac.2025.102704_bib37","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/myc.13465","article-title":"Prevalence of chronic pulmonary aspergillosis regarding time of tuberculosis diagnosis in Brazil","volume":"65","author":"Volpe-Chaves","year":"2022","journal-title":"Mycoses"},{"issue":"9","key":"10.1016\/j.jiac.2025.102704_bib38","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/myc.13300","article-title":"Concomitant use of isavuconazole and CYP3A4\/5 inducers: where pharmacogenetics meets pharmacokinetics","volume":"64","author":"Van Daele","year":"2021","journal-title":"Mycoses"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X25001011?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X25001011?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T07:16:56Z","timestamp":1748503016000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X25001011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S1341321X25001011"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2025.102704","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Isavuconazole in chronic pulmonary aspergillosis: What is the evidence?","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2025.102704","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102704"}}